Federal State Institution
"State Institute of Drugs and Good Practices"
(FSI "SID & GP")



A survey of pharmaceutical manufacturers on the readiness for the introduction of a labeling system



STAGES AND POLLING RESULTS OF RUSSIAN LICENSEES

FIRST STAGE

Last October
we requested data from
493 Russian
license
holders reflecting costs for
re-equipment of packaging
lines for different pharmaceutical products.









STAGES AND POLLING RESULTS OF RUSSIAN LICENSEES

SECOND STAGE

In November 2017, during the second stage, we requested that companies file in data on the number of lines planned for commissioning within the drugs labeling system. The submission deadline was December 5, 2017. Received detailed reports allowed to present a comprehensive summary in late January 2018. я

1000 packaging lines will be commissioned individual labeling system





STAGES AND POLLING RESULTS OF RUSSIAN LICENSEES

THIRD STAGE

During the 3rd stage of these polling activities in February 2018, we asked Russian manufacturers to share their timelines for produced drugs to be entered into the automated monitoring system of INN. Calendars received from the manufacturers with schedules of drugs entered into the INN system, were relayed to the Ministry of Industry and Trade in late 2018.

RECEIVED


225 responses from manufacturers out of

468 contacted companies.

Total number of license holders is 539



RESULTS DEMONSTRATED





FOREIGN MANUFACTURERS SURVEY

Number of foreign production sites

as of 20.04.2018 responses were received from four pharmaceutical manufacturers (17 production sites)

1708

107

INN 7N

55 INN EDL

In total, as reported by the Rissian MoH on 17.01.2018, there are almost two thousand foreign to Russia sites (1708). Starting this April - on a monthly basis - our Institute presents a consolidated report to the Ministry of Industry and Trade based on surveys of foreign manufacturers.

The survey is currently in process, and some pieces of information are still on the way. The latest on that is as follows: on April 20, 2018 we received four pharmaceutical manufacturers (17 production sites, 5 holders of marketing authorizations: KEDRION (Italy), Swedish Orphan Biovibrum International AB (Sweden), Hetero Labs Lt. (India), Gedeon Richter (Hungary). In total it makes 107 INN, 4 of them are 7N µ 55 - EDL.

MINISTRY OF INDUSTRY AND TRADE OF THE RUSSIAN FEDERATION

